AstraZeneca Educational Webinar Series

Presented by ADCES in association with AstraZeneca-US Medical Affairs, CVMD Division

This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 90 days after the live broadcast, so don't miss out!

This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.






2020 Webinar Schedule:

All webinars will be held 1:00 - 2:00 pm EST.

February 26:  GLP-1 Physiology and Evolving Clinical Data  (Click here to register today!)

March 18:  Measures Beyond A1C and Their Impact on Treatment

May 27:  Heart Failure Associated with Type 2 Diabetes 

June 24:  2020 Guideline Updates and Implications to Patient Care

July 22:  Cardiovascular Disease and Type 2 Diabetes: Defining the Therapeutic Crossroads

September 23:  Relationship of Type 2 Diabetes and Diabetic Kidney Disease: Progression of these chronic conditions

October 21:  Type 2 Diabetes and Kidney Disease: Patient engagement and how to manage chronic conditions

December 2:  SGLT-2 Inhibitor Overview and Emphasis on Cardio-Renal Axis





GLP-1 Physiology and Evolving Clinical Data

James A. Ruggles, PhD, and Curtis Triplitt, PharmD, CDE

This webinar will provide an overview of the actions of GLP-1 receptor agonists in the body, the clinical effects of GLP-1 receptor agonists on glycemia, MACE, and renal endpoints; as well as the impact of higher concentrations on weight.

Wednesday, February 26, 2020 at 1:00 pm EST

Click here to register today!​

   
   
    

Measures Beyond A1C and
Their Impact on Treatment

Jonathan A. Respress, PhD

This webinar will go over how PPG and FPG impact A1C and what the impact of glucose-dependency and treatment options is. The presenters will also provide an understanding the role of CGM and its impact on treatment decisions, as well as what “time in range” is and why it matters.

Wednesday, March 18, 2020 at 1:00 pm EST

   
   

Heart Failure Associated with Type 2 Diabetes

Susan Thomas, MD and Jonathan A. Respress, PhD

This webinar will provide a basic overview of diabetic / non-diabetic cardiomyopathy and clinical perspectives on HFpEF and HFrEF. Participants will be able to understand treatment options for HF in patients with and without diabnetes.

Wednesday, May 27, 2020 at 1:00 pm EST

  
  
    

2020 Guideline Updates and Implications
to Patient Care

Ted Okerson and Paul Tomasic

Understand changes to the ADA/EASD treatment guidelines and importance of treating CVD and DKD as well as the impact of treatments on glycemia and weight. The presenters will facilitate a discussion on this impact to providers and patients.

Wednesday, June 24, 2020 at 1:00 pm EST

  
  

Cardiovascular Disease and Type 2 Diabetes:
Defining the Therapeutic Crossroads

John Venditto, MD

Explore the relationships between type 2 diabetes and cardiovascular disease (CVD) with CVD risk factors. The presenter will discuss definitions of primary and secondary prevention of CVD, including long-term oral anti-platelet trials in secondary prevention in T2D. You'll come away with an understanding of lipid and triglyceride management.

Wednesday, July 22, 2020 at 1:00 pm EST

    
    
    

Relationship of Type 2 Diabetes and Diabetic Kidney Disease: Progression of these chronic conditions

Robert M. Perkins, MD, MPH

This webinar will give you an understanding of how type 2 diabetes and diabetic kidney disease (DKD) are related. Understand the continuum of disease progression and key points of intervention, as well as the treatment options when treating complications of DKD.

Wednesday, September 23, 2020 at 1:00 pm EST

    
    

Type 2 Diabetes and Kidney Disease: Patient engagement and how to manage chronic conditions

Robert M. Perkins, MD, MPH and Ted Okerson

Understand key points of clinical intervention, as well as how to engage patients in discussions about chronic conditions early in development of disease, and how to encourage adopting healthy behaviors.

Wednesday, October 21, 2020 at 1:00 pm EST

    

SGLT-2 Inhibitor Overview and Emphasis
on Cardio-Renal Axis

Speaker TBA

This webinar will go over how SGLT-2 inhibition impacts the physiology of the kidney and heart. Understand the clinical effects on glycemia, MACE, hHF, and renal endpoints in diabetes, as well as the evolving landscape and use of these agents in patients without diabetes.

Wednesday, December 2, 2020 at 1:00 pm EST

  


  

Recorded webinar:

Managing Heart Failure Risks in People with Diabetes: New Clinical Trials with SGLT-2 Inhibitors


Originally presented on December 4, 2019 by Like Jiang, MD, and Curtis Triplitt, PharmD, CDE

This webinar provides the evidence of increased risks of heart failure for people with type 2 diabetes and how SGLT-2 inhibitors may play a role in reducing the risk.

Upon completion of this activity, participants will be able to:

  1. Understand the risk of heart failure in people with type 2 diabetes
  2. Understand the data from recent cardiovascular and heart failure studies from SGLT-2 inhibitors
  3. Understand the guidelines and recommendations